UPDATE – Landing Partners with CLEAR to Bring New Level of Security and Convenience to Apartment Rentals
19. Dezember 2023 10:24 ET
|
Landing
BIRMINGHAM, Ala., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Landing, the company behind the first membership for flexible apartment living, has partnered with CLEAR, the secure identity company, to...
The Clear Cannabis Announces Expansion into Arkansas Market
19. April 2023 10:00 ET
|
The Clear Cannabis
DENVER, April 19, 2023 (GLOBE NEWSWIRE) -- Clear Cannabis Inc.™, a national licensor of The Clear™, a legacy cannabis brand of innovative and high quality distilled concentrate products, has...
Zuora Recognized as a Global Leader in the First IDC MarketScape for Subscription Relationship Management
27. November 2017 10:00 ET
|
Zuora, Inc.
SAN MATEO, Calif., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Zuora, Inc., the leading SaaS provider of subscription order-to-cash solutions, was named a Leader in the IDC MarketScape: Worldwide Subscription...
Esperion Completes Patient Enrollment in Global Pivotal Phase 3 Program for Bempedoic Acid
02. Oktober 2017 16:30 ET
|
Esperion Therapeutics, Inc.
– Pivotal Phase 3 Top-Line Results for Bempedoic Acid Expected in the Second and Third Quarters of 2018 –– NDA Submission for LDL-C Lowering Indication for Bempedoic Acid Planned by First Quarter 2019...
Esperion to Present at the 35th Annual J.P. Morgan Healthcare Conference
04. Januar 2017 17:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing complementary oral therapies for...
Esperion Therapeutics to Present at the Stifel 2016 Healthcare Conference
09. November 2016 16:30 ET
|
Esperion Therapeutics, Inc.
Presentation and Webcast on Wednesday, November 16, 2016 at 3:00 p.m. Eastern Time ANN ARBOR, Mich., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical...
Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Third Quarter 2016 Financial Results
03. November 2016 16:05 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing oral therapies for the treatment...
Bempedoic Acid Global Phase 3 Clinical Program to Include Patients on Any Statin at Any Dose
13. Oktober 2016 07:30 ET
|
Esperion Therapeutics, Inc.
1002-035 Study Meets Primary Endpoint of Incremental LDL-C Lowering Added to Atorvastatin 80 mgBempedoic Acid Had No Effect on the PK of Atorvastatin and Was Observed to be Safe and...
Solar Control Window Films Market size worth USD 1.71 billion by 2024, at over 11% CAGR from 2016 to 2024: Global Market Insights Inc.
27. Juli 2016 11:00 ET
|
Global Market Insights
Ocean View, Delaware, July 27, 2016 (GLOBE NEWSWIRE) -- Solar Control Window Films Market size is expected to reach USD 1.71 billion by 2024; according to a new research report by Global...
Esperion Therapeutics Provides Clinical Development and Regulatory Update for Bempedoic Acid
28. Juni 2016 16:05 ET
|
Esperion Therapeutics, Inc.
On track to initiate global pivotal Phase 3 studies and CVOT in the fourth quarter Aligned with global regulatory authorities on a consistent definition of statin intolerance Conference...